Previous close | 104.05 |
Open | 106.53 |
Bid | 105.10 x 1000 |
Ask | 108.12 x 1800 |
Day's range | 106.35 - 108.19 |
52-week range | 78.71 - 122.16 |
Volume | |
Avg. volume | 1,521,222 |
Market cap | 245.625B |
Beta (5Y monthly) | 0.32 |
PE ratio (TTM) | 35.49 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.57 (1.48%) |
Ex-dividend date | 25 Mar 2022 |
1y target est | N/A |
Eli Lilly (NYSE: LLY) is a top healthcare company that continually finds new ways to grow and create value for its investors. One of the company's recent diabetes treatments has obtained approval from the U.S. Food and Drug Administration (FDA). On May 13, Eli Lilly announced that the FDA had approved Mounjaro (tirzepatide) to treat people with type 2 diabetes.
Eli Lilly, Novo Nordisk, Merck, and Glaxo are part of Zacks Industry Outlook article.
Drug/biotech companies are likely to see significant advances in innovation in 2022. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Glaxo (GSK) are worth retaining in your portfolio.